The Experts below are selected from a list of 4218 Experts worldwide ranked by ideXlab platform
Fabrice Gallou - One of the best experts on this subject based on the ideXlab platform.
-
Inspiring process innovation via a breakthrough green manufacturing metric: iGAL
2018Co-Authors: Fabrice GallouAbstract:Following our goal to devise a unified green chemistry metric that inspires innovation in sustainable Drug manufacturing across the pharmaceutical industry, we herein disclose our efforts leading to the breakthrough ‘innovation Green Aspiration Level’ (iGAL) methodology. Backed by the statistical analysis of 64 Drug manufacturing processes across 12 companies, we find that iGAL affords a suitable proxy for molecular complexity and presents a valuable molecular weight-based ‘fixed’ goal. iGAL thereby accurately captures the impact of green process inventiveness and improvements, rendering it an outstanding innovation-driven green metric. We conclude by introducing the comprehensive, yet easy-to-use and readily adaptable Green Chemistry Innovation Scorecard web calculator, whose graphical output clearly and effectively illustrates the impact of innovation on waste reduction during Drug Manufacture.
-
Inspiring process innovation via an improved green manufacturing metric: iGAL
Green Chemistry, 2018Co-Authors: Frank Roschangar, Fabrice Gallou, Yanyan Zhou, David J. C. Constable, Juan Carlos Colberg, David P. Dickson, Peter J. Dunn, Martin D. Eastgate, John D. Hayler, Stefan G. KoenigAbstract:Following our goal to devise a unified green chemistry metric that inspires innovation in sustainable Drug manufacturing across the pharmaceutical industry, we herein disclose joint efforts by IQ, the ACS GCI PR and academia, leading to the significantly improved ‘innovation Green Aspiration Level’ (iGAL) methodology. Backed by the statistical analysis of 64 Drug manufacturing processes encompassing 703 steps across 12 companies, we find that iGAL affords an excellent proxy for molecular complexity and presents a valuable molecular weight-based ‘fixed’ goal. iGAL thereby accurately captures the impact of green process inventiveness and improvements, making it a useful innovation-driven green metric. We conclude by introducing the comprehensive, yet easy-to-use and readily adaptable Green Chemistry Innovation Scorecard web calculator, whose graphical output clearly and effectively illustrates the impact of innovation on waste reduction during Drug Manufacture.
Stefan G. Koenig - One of the best experts on this subject based on the ideXlab platform.
-
Inspiring process innovation via an improved green manufacturing metric: iGAL
Green Chemistry, 2018Co-Authors: Frank Roschangar, Fabrice Gallou, Yanyan Zhou, David J. C. Constable, Juan Carlos Colberg, David P. Dickson, Peter J. Dunn, Martin D. Eastgate, John D. Hayler, Stefan G. KoenigAbstract:Following our goal to devise a unified green chemistry metric that inspires innovation in sustainable Drug manufacturing across the pharmaceutical industry, we herein disclose joint efforts by IQ, the ACS GCI PR and academia, leading to the significantly improved ‘innovation Green Aspiration Level’ (iGAL) methodology. Backed by the statistical analysis of 64 Drug manufacturing processes encompassing 703 steps across 12 companies, we find that iGAL affords an excellent proxy for molecular complexity and presents a valuable molecular weight-based ‘fixed’ goal. iGAL thereby accurately captures the impact of green process inventiveness and improvements, making it a useful innovation-driven green metric. We conclude by introducing the comprehensive, yet easy-to-use and readily adaptable Green Chemistry Innovation Scorecard web calculator, whose graphical output clearly and effectively illustrates the impact of innovation on waste reduction during Drug Manufacture.
Joel M Hawkins - One of the best experts on this subject based on the ideXlab platform.
-
organic chemistry streamlining Drug synthesis
Nature, 2015Co-Authors: Joel M HawkinsAbstract:Drug Manufacture can benefit from flow synthesis, in which raw materials are fed into a sequence of reactors, producing the Drug as a continuous output. A flow strategy that capitalizes on solid catalysts has now been realized. See Letter p.329
Frank Roschangar - One of the best experts on this subject based on the ideXlab platform.
-
Inspiring process innovation via an improved green manufacturing metric: iGAL
Green Chemistry, 2018Co-Authors: Frank Roschangar, Fabrice Gallou, Yanyan Zhou, David J. C. Constable, Juan Carlos Colberg, David P. Dickson, Peter J. Dunn, Martin D. Eastgate, John D. Hayler, Stefan G. KoenigAbstract:Following our goal to devise a unified green chemistry metric that inspires innovation in sustainable Drug manufacturing across the pharmaceutical industry, we herein disclose joint efforts by IQ, the ACS GCI PR and academia, leading to the significantly improved ‘innovation Green Aspiration Level’ (iGAL) methodology. Backed by the statistical analysis of 64 Drug manufacturing processes encompassing 703 steps across 12 companies, we find that iGAL affords an excellent proxy for molecular complexity and presents a valuable molecular weight-based ‘fixed’ goal. iGAL thereby accurately captures the impact of green process inventiveness and improvements, making it a useful innovation-driven green metric. We conclude by introducing the comprehensive, yet easy-to-use and readily adaptable Green Chemistry Innovation Scorecard web calculator, whose graphical output clearly and effectively illustrates the impact of innovation on waste reduction during Drug Manufacture.
Karen Mcmillan - One of the best experts on this subject based on the ideXlab platform.
-
Injury associated with methamphetamine use: A review of the literature
Harm Reduction Journal, 2006Co-Authors: Janie Sheridan, Sara Bennett, Carolyn Coggan, Amanda Wheeler, Karen McmillanAbstract:This paper reviews the literature exploring issues around methamphetamine and injury. There was a paucity of peer reviewed quantitative research and a lack of large scale epidemiological studies. Further sources described cases and others described injury risk as part of an overall review of methamphetamine misuse. Thus, a number of limitations and potential biases exist within the literature. The main areas where associations were noted or extrapolated with methamphetamine use and injury were around driving and violence. Other associations with injury related to methamphetamine Manufacture. There was also circumstantial evidence for third party injury (that is injury to those not specifically involved in Drug use or Drug Manufacture); however, the available data are inadequate to confirm these associations/risks.
